Miromatrix to Ring Nasdaq Closing Bell on National Donor Day, February 14, 2022
February 10 2022 - 6:00AM
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company
pioneering a novel technology for bioengineering fully
transplantable organs to help save and improve patients’ lives,
announced that the Company will ring the closing bell at Nasdaq on
Monday, February 14, 2022, at 4:00 p.m. ET to celebrate National
Donor Day and the Company’s public listing last year on Nasdaq
under the trading symbol MIRO.
Miromatrix CEO, Jeff Ross, Ph.D., will ring the
closing bell alongside the Company’s team and representatives from
strategic investors, including Baxter (NYSE: BAX), CareDx (NASDAQ:
CDNA), and DaVita (NYSE: DVA).
“We are thrilled to celebrate such an important
milestone for Miromatrix with our team, collaborators, and
investors,” said Jeff Ross, Ph.D., Miromatrix CEO. “We remain
steadfast in our mission of bioengineering fully transplantable
human organs. Thanks to the dedication and hard work of the
Miromatrix team, we have accomplished a great deal this past year,
including our recent pre-IND request to the FDA for our External
Liver Assist Product for the treatment of acute liver failure. We
will continue to drive our objectives forward as we strive towards
eliminating the organ transplant waitlist. It’s especially
appropriate on National Donor Day as we honor all those who have
given and received the gift of life through the national donor
program.”
The ceremony will begin at approximately 3:30 p.m.
ET on Monday, February 14, 2022, and can be viewed live here.
A replay of the ceremony will be available at a later date on the
Events & Presentations page of the Investors section of
Miromatrix’s website.
About MiromatrixMiromatrix Medical
Inc. is a life sciences company pioneering a novel technology for
bioengineering fully transplantable human organs to help save and
improve patients’ lives. The Company has developed a proprietary
perfusion technology platform for bioengineering organs that it
believes will efficiently scale to address the shortage of
available human organs. The Company’s initial development focus is
on human livers and kidneys. For more information,
visit miromatrix.com.
Cautionary Statement Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements other than
statements of historical facts are forward looking statements,
including statements regarding our first ever transplant of a
bioengineered liver transplant into a large animal. In some cases,
you can identify forward-looking statements by terms such as “may,”
“will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“outlook,” “guidance,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential” or
“continue” or the negative of these terms or other similar
expressions, although not all forward-looking statements contain
these words. The forward-looking statements in this press release
are only predictions and are based largely on our current business
plans, expectations, and projections about future events and
financial trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of known and unknown risks, uncertainties and
assumptions, including, but not limited to, our history of
significant losses, which we expect to continue; our limited
history operating as a commercial company; our expectations with
respect to the regulatory pathway of our product candidates, our
ability to obtain regulatory approvals for such product candidates,
and the anticipated effect of delays in obtaining any such
regulatory approvals; our expectations with respect to preclinical
and clinical trial plans for our product candidates, the results of
such activities and the safety and efficacy of our product
candidates; our ability to commercialize our product candidates;
our ability to compete successfully with larger competitors in our
highly competitive industry; our ability to achieve and maintain
adequate levels of coverage or reimbursement for any future
products we may seek to commercialize; our ability to compete
successfully with larger competitors in our highly competitive
industry; our expectations regarding our manufacturing
capabilities; a pandemic, epidemic or outbreak of an infectious
disease in the U.S. or worldwide, including the outbreak of the
novel strain of coronavirus, COVID-19; product liability claims;
our ability to establish and maintain intellectual property
protection for our products, as well as our ability to operate our
business without infringing the intellectual property rights of
others; our ability to attract and retain senior management and key
scientific personnel; and other important factors that could cause
actual results, performance or achievements to differ materially
from those expected or projected. For information identifying
important factors that could cause actual results to differ
materially from those anticipated in the forward-looking
statements, please refer to the Risk Factors section of the
Company’s Registration Statement on Form S-1 (File No. 333-256649),
as amended, filed with the U.S. Securities and Exchange Commission
and any additional risks presented in our Quarterly Reports on Form
10-Q and our Current Reports on Form 8-K. Except as expressly
required by applicable securities law, the Company disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information, future events or
otherwise.
Investor ContactGreg
Chodaczek332-895-3230ir@miromatrix.com
Media
Contact:press@miromatrix.com
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jul 2023 to Jul 2024